Skip to content

Moderate Alcohol Consumption, Risk of Cardiovascular Disease and Type 2 Diabetes: Influence of Alcohol Oxidation

Effect of Moderate Alcohol Consumption on PPAR-γ Activity and Risk Markers of Metabolic Disease: Influence of Genetic Variation in Alcohol Oxidation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00285909
Enrollment
36
Registered
2006-02-02
Start date
2006-03-31
Completion date
2006-06-30
Last updated
2006-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Type 2 Diabetes

Keywords

Moderate alcohol consumption, Alcohol dehydrogenase 1c polymorphism, PPAR-gamma activated gene expression

Brief summary

Moderate alcohol consumption is associated with a decreased risk of cardiovascular disease and type 2 diabetes. The association of alcohol consumption with cardiovascular disease is mediated by a functional polymorphism of alcohol dehydrogenase 1c, but the effect of this polymorphism on alcohol metabolism is only investigated in vitro. The risk reduction of moderate alcohol consumption for cardiovascular disease is explained largely by an increase of HDL cholesterol, but an increase of adiponectin concentrations after moderate alcohol consumption may also be involved. It seems likely that adiponectin is a mediator for the association of moderate alcohol consumption with type 2 diabetes. The mechanism by which moderate alcohol consumption increases adiponectin concentrations is unknown, but ppar-gamma activation may be involved. effects of this polymorphism on mediators of this relation are not known. This study therefore investigates the effect of moderate alcohol consumption and the influence of alcohol dehydrogenase 1c polymorphism on ppar-gamma activated gene expression and risk factors of cardiovascular disease and type 2 diabetes.

Detailed description

Objectives : To investigate the effect of moderate alcohol consumption and influence of genetic variation of ethanol oxidation on: * PPAR-γ activated gene expression * Markers of coronary heart disease or type 2 diabetes * Postprandial changes of HPA-axis activity among 36 postmenopausal women with ADH1C genotype associated with slow or fast alcohol metabolism. Design : Randomized, controlled, not blinded crossover trial with 1 week wash-out preceding each treatment period Participants * Description : Apparently healthy postmenopausal women * Number : 36 Study substances * Test substance : White wine (ca. 25 g alcohol/day) * Reference substance : White grape juice Study treatments Treatment A: 250 ml white wine daily (ca. 25 g alcohol/day) Treatment B: 250 ml white grape juice daily Study period \- Duration : two periods of 6 weeks preceded by 1 week wash-out period Test parameters: * Adiponectin mRNA expression * Expression of PPAR-gamma activated genes: CD36, lipoprotein lipase, AP2 * Markers of cardiovascular disease (blood lipid profile, Lp-PLA2 activity, hs-CRP, fibrinogen) * Markers of type 2 diabetes (adiponectin, adiponectin oligomers, insulin sensitivity) * Parameters of alcohol oxidation (postprandial: blood alcohol and acetate, acetaldehyde) * HPA-axis activity (postprandial & fasting: cortisol, ACTH, testosterone)

Interventions

BEHAVIORALAlcohol: 25 gday (white wine)

Sponsors

TNO
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy women aged 40 to 65 years * Absence of menstrual period for at least 2 years * Homozygotes for the ADH1C\*1 or ADH1C\*2 allele of ADH1C I349V polymorphism * Alcohol consumption ≥ 5 and ≤ 21 units/week

Exclusion criteria

* Smoking * Family history of alcoholism * History of medical or surgical events that may significantly affect the study outcome, particularly metabolic or endocrine disorders and gastrointestinal disorders * Recent blood donation

Design outcomes

Primary

MeasureTime frame
PPAR-gamma activated gene expression

Secondary

MeasureTime frame
Risk factors of cardiovascular disease and type 2 diabetes
Postprandial changes of HPA-axis activity

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026